Clinical Trial Update: Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days [Phase 1]

View source ↗

Summary

A Phase 1 study of the SS1(dsFv)-PE38 (SS1P) anti-mesothelin immunotoxin in advanced malignancies was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SS1(dsFv)-PE38 (SS1P) (SS1P)

Snippet

Sponsor: INSYS Therapeutics Inc | Conditions: Neoplasms | Phase 1 | Status: WITHDRAWN